Back

Clinical features and long-term outcomes of cancer-associated venous thromboembolism: transition from the warfarin era to the direct oral anticoagulant era

28 August 2023 (09:42 - 10:00)
Organised by: Logo
Congress Presentation Part of: Prediction and management of cardiovascular risk for patients with cancer Cardio-Oncology ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Ryuki Chatani

Kurashiki Central Hospital, Kurashiki (Japan)

4 More presentations in this session

Presentation thumbnail
State-of-the-art lecture on prediction and management of cardiovascular risk in cancer patients
Doctor A. Lyon (London, GB)
Slides Video
Presentation thumbnail
Androgen deprivation therapy for prostate cancer, measures of adiposity and strength, and adverse cardiovascular outcomes: observations from 3000 men in 5 countries in the RADICAL PC study
Doctor D. Leong (Hamilton, CA)
Abstract Slides Video
Presentation thumbnail
Risk prediction model of cardiotoxicity in breast cancer patients; the multicenter prospective CHECK HEART-BC (comprehensive heart imaging to evaluate cardiac damage linked with chemotherapy in breast
Doctor Y. Terui (Sendai, JP)
Abstract Slides Video
Presentation thumbnail
Right ventricular free wall strain and tricuspid annular plane systolic excursion for the prediction of left sided cardiotoxicity in lymphoma patients treated with anthracycline-based chemotherapy.
Doctor C. Ricaurte Carmona (Rochester, US)
Abstract Slides Video

Access the full session

Session thumbnail
Prediction and management of cardiovascular risk for patients with cancer
Video

The Event

Event poster

ESC Congress 2023

28 August 2023 09:42 CET
You may be interested in
thumbnail
Congress Presentation
Clinical features and long-term outcomes of venous thromboembolism in the warfarin era versus in the direct oral anticoagulant era
thumbnail
Congress Presentation
The initial high-dose versus maintenance-dose anticoagulation therapy with direct oral anticoagulants for cancer-associated venous thromboembolism: from the COMMAND VTE Registry-2
thumbnail
Congress Presentation
The influence of concomitant antiplatelet therapy in venous thromboembolism patients treated with anticoagulants in the DOAC era: insight from the COMMAND VTE Registry-2

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources